JP2014518630A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518630A5
JP2014518630A5 JP2014513202A JP2014513202A JP2014518630A5 JP 2014518630 A5 JP2014518630 A5 JP 2014518630A5 JP 2014513202 A JP2014513202 A JP 2014513202A JP 2014513202 A JP2014513202 A JP 2014513202A JP 2014518630 A5 JP2014518630 A5 JP 2014518630A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
sequence
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014513202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518630A (ja
JP6254522B2 (ja
Filing date
Publication date
Priority claimed from GBGB1109238.4A external-priority patent/GB201109238D0/en
Application filed filed Critical
Publication of JP2014518630A publication Critical patent/JP2014518630A/ja
Publication of JP2014518630A5 publication Critical patent/JP2014518630A5/ja
Application granted granted Critical
Publication of JP6254522B2 publication Critical patent/JP6254522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014513202A 2011-06-01 2012-06-01 ヒト化抗cd52抗体 Active JP6254522B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161492005P 2011-06-01 2011-06-01
GBGB1109238.4A GB201109238D0 (en) 2011-06-01 2011-06-01 Antibodies
US61/492,005 2011-06-01
GB1109238.4 2011-06-01
PCT/EP2012/060345 WO2012164063A1 (en) 2011-06-01 2012-06-01 Humanised anti-cd52 antibodies

Publications (3)

Publication Number Publication Date
JP2014518630A JP2014518630A (ja) 2014-08-07
JP2014518630A5 true JP2014518630A5 (enExample) 2015-07-16
JP6254522B2 JP6254522B2 (ja) 2017-12-27

Family

ID=44310746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513202A Active JP6254522B2 (ja) 2011-06-01 2012-06-01 ヒト化抗cd52抗体

Country Status (16)

Country Link
US (1) US9321841B2 (enExample)
EP (1) EP2714739A1 (enExample)
JP (1) JP6254522B2 (enExample)
KR (1) KR20140036274A (enExample)
CN (1) CN103649122B (enExample)
AU (1) AU2012264643B2 (enExample)
BR (1) BR112013030875A2 (enExample)
CA (1) CA2837965A1 (enExample)
GB (1) GB201109238D0 (enExample)
IL (1) IL229713A (enExample)
MX (1) MX342676B (enExample)
MY (1) MY163257A (enExample)
RU (1) RU2605307C2 (enExample)
SG (1) SG195042A1 (enExample)
WO (1) WO2012164063A1 (enExample)
ZA (1) ZA201308900B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 cd52 면역글루불린
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
CN106018814B (zh) * 2016-08-07 2017-11-14 深圳市南海生物科技有限公司 一种用于白血病和自身免疫病检测用试剂盒
EP3612564A2 (en) * 2017-04-21 2020-02-26 Genzyme Corporation Treatment of multiple sclerosis with anti-cd52 antibodies
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN117534750B (zh) * 2023-10-16 2024-06-11 遵义医科大学珠海校区 一种抗新型冠状病毒核衣壳蛋白的抗体或其抗原结合片段及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1989007452A1 (en) * 1988-02-12 1989-08-24 Medical Research Council Improvements in or relating to antibodies
GB9022547D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9603507D0 (en) * 1996-02-20 1996-04-17 Isis Innovation Antibody variants
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU9399501A (en) * 2000-10-09 2002-04-22 Isis Innovation Therapeutic antibodies
CA2499816C (en) * 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗cd52抗体
JP2007515492A (ja) * 2003-12-22 2007-06-14 ジェンザイム コーポレイション 糖尿病の抗cd52抗体治療法
CN101115771B (zh) 2005-02-03 2013-06-05 安迪拓普有限公司 人类抗体和蛋白质
EP1883653A2 (en) * 2005-05-24 2008-02-06 Avestha Gengraine Technologies Pvt. Ltd. Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
KR20160005143A (ko) 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 cd52 면역글루불린
CN102079787A (zh) * 2010-12-09 2011-06-01 协和干细胞基因工程有限公司 抗人cd52的工程抗体、载体、试剂盒及其用途

Similar Documents

Publication Publication Date Title
JP2014518630A5 (enExample)
RU2013158454A (ru) Гуманизированные антитела к сd52
CN112574307B (zh) 抗人Claudin18.2抗体及其应用
JP2014512809A5 (enExample)
JP2020522261A5 (enExample)
US9771424B2 (en) ICOS binding proteins
RU2013145243A (ru) Гуманизированные антитела к ctla4
Vardi et al. Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution
JP2021500916A5 (enExample)
CN103172738A (zh) Il-12/p40结合蛋白
PE20181952A1 (es) Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos
CN109379892A (zh) 抗-IgE抗体
JP2015534982A5 (enExample)
ME02678B (me) Antitijela na ox-40 i postupci njihove primjene
TW201414747A (zh) Il-18結合分子
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
PE20170687A1 (es) Proteinas de enlace a cd127
JP2016529882A5 (enExample)
JP2019534892A5 (enExample)
TW201134489A (en) Basigin binding proteins
RU2016106708A (ru) Лекарственное средство, содержащее антитело к фосфолипазе d4
Teng et al. SARS-CoV-2 spike-reactive naïve B cells and pre-existing memory B cells contribute to antibody responses in unexposed individuals after vaccination
CN110494447B (zh) 使用抗人gpv1抗体抑制血小板聚集
US20210317405A1 (en) Methods for the production of therapeutic, diagnostic, or research antibodies
JP2020521752A (ja) グロボhに対するヒト化抗体および癌治療におけるその使用